^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Colorectal Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients

    Excerpt:
    ...Histologically confirmed diagnosis of colorectal cancer RAS/BRAF mutated....
    Trial ID:
    NIVACOR
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase II Study on NIVolumab in combination with FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan)/Bevacizumab in first line chemotherapy of Advanced COloRectal cancer patients with mutated RAS or BRAF genes. Studio di fase II con Nivolumab in combinazione con FOLFOXIRI (fluorouracile, acido folinico, oxaliplatino e irinotecano)/Bevacizumab come trattamento di I linea in pazienti con tumore colorettale avanzato con mutazione dei geni RAS o BRAF.

    Excerpt:
    ...• Age = 18 years on day of signing informed consent.• Histologically confirmed metastatic CRC RAS/BRAF mutated.• Suitable for first line chemotherapy.• Life expectancy > 3 months.• At least one site of measurable disease per RECIST criteria.• Performance status of 0-1 on the ECOG Performance Scale.• Adequate organ function, all screening labs should be performed within 28 days of treatment initiation.• Availability of 1 tumor block at baseline. ...
    Trial ID:
    2018-002893-38
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018).

    Published date:
    05/26/2022
    Excerpt:
    In subgroups analysis of MSS pts the ORR was 78.9% with a mDOR of 7.59 (95% CI 6.21 -11.43) months, DCR of 96.2%, and mPFS of 9.8 (95%CI 8.18-15.24) months….The primary endpoint ORR was met. These results show the preliminary efficacy and safety of NIV in combination with FOLOXIRI/BEV as first-line therapy in pts with mCRC RAS/BRAF mut.
    Secondary therapy:
    FOLFOXIRI
    DOI:
    10.1200/JCO.2022.40.16_suppl.3509
    Trial ID:
    NIVACOR